Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : biotech fireworks -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (1832)	1/6/2005 2:09:47 PM
From: tuck	Respond to of 7424

Penny stock VITX up almost 60% on merger partner Panacos' HIV drug getting Fast Tracked: >>GAITHERSBURG Md., Jan. 6 /PRNewswire/ -- Panacos Pharmaceuticals, Inc., today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for PA-457, the Company's once-daily oral drug candidate for the treatment of HIV infection. PA-457 is the first in a new class of HIV drugs called Maturation Inhibitors. Fast Track is a process designed to expedite development and approval of new drugs that may have the potential to improve treatment for serious or life-threatening diseases. In granting Fast Track status for the form of PA-457 that is currently being tested in human clinical trials, FDA noted that this is a drug to treat a serious or life-threatening condition with an unmet medical need. Developers of Fast Tracked products have greater access to FDA resources as well as eligibility for rolling NDA submissions. In addition, Fast Track designation may enable priority FDA review and accelerated approval. "We believe that PA-457 has great potential as a new approach to treat HIV/AIDS and are very pleased that the FDA has chosen to grant Fast Track status, which we believe will allow us to expedite development of this drug," commented Dr. Graham Allaway, Panacos' Chief Operating Officer. "There is a major need for treatments effective against drug-resistant strains of HIV, which appear in most patients receiving therapy and are the leading cause of treatment failure. PA-457 has a different mechanism of action than approved HIV drugs and as a result it potently inhibits HIV strains resistant to currently available treatments as well as wild-type virus." Panacos has completed single dose (Phase Ia) and multiple dose (Phase Ib) studies of PA-457 in uninfected volunteers, demonstrating that the drug is well tolerated with pharmacokinetics supporting once-daily oral dosing. Furthermore, the Company recently announced positive results from a proof-of- concept Phase I/II clinical trial of PA-457 in HIV-infected patients, where a single oral dose of the drug gave a significant reduction in plasma viral load from baseline, of up to approximately 0.7 log10 at the higher dose levels. Full results of the Phase Ib and Phase I/II clinical trials of PA-457 will be provided at the 12th Conference on Retroviruses and Opportunistic Infections to be held in Boston, MA, during February, 2005. In December 2004, the Company initiated a Phase IIa clinical trial of PA- 457. This study, being performed at multiple sites in the U.S., is designed to evaluate the antiviral potency of PA-457 following once-daily oral dosing for 10 days, in HIV-infected patients who are not on other antiretroviral therapy. Dr. David E. Martin, Senior Vice President of Drug Development at Panacos, said: "We were excited to see a significant reduction in viral load following a single oral dose of PA-457 and we anticipate an even greater viral load reduction in the multiple dose Phase IIa study. The granting of Fast Track status will enable us to get rapid input and feedback from FDA on our clinical program, and we believe that it will help us move PA-457 quickly into late stage clinical development." Results of the Phase IIa clinical trial are expected in Q2, 2005. During the second half of 2005, Panacos intends to initiate Phase IIb studies of PA-457 designed to pave the way for pivotal Phase III studies beginning in 2006. About PA-457 PA-457 is a small molecule, orally bioavailable HIV drug candidate. It inhibits HIV replication by disrupting virus maturation, the last step in the virus life-cycle. This novel mechanism was discovered by Panacos scientists and is different from the mode of action of approved drugs or other drugs in development. Specifically, PA-457 blocks a key step in the processing of a viral core protein called capsid. Preclinical studies have shown that PA-457 retains full activity against drug-resistant virus and is effective in an animal model of HIV infection. The form of PA-457 currently being tested in human clinical trials is designated PA-103001-01. About Panacos Panacos Pharmaceuticals is engaged in the discovery and development of small molecule oral drugs for the treatment of HIV and other major human viral diseases. Panacos' proprietary discovery technologies focus on novel targets in the virus life cycle, including virus fusion and virus maturation, the first and last steps of viral infection. On June 2, 2004, Panacos Pharmaceuticals entered into a definitive merger agreement with V.I. Technologies, Inc. (Nasdaq: VITX - News), a biotechnology company dedicated to developing novel anti-infective technologies. The terms of the merger were amended on November 5, 2004, November 29, 2004 and December 8, 2004. The transaction is expected to close in the first quarter of 2005 and is subject to the approval by shareholders of both companies and other customary closing conditions.<< snip Cheers, Tuck